Hypogonadism

Summary

Hypogonadism (MONDO:0002146) is a disease (an umbrella term covering 6 Mondo subtypes) with 3 cohort genes (136 GWAS associations across 5 studies) and 197 clinical trials. Top therapeutic interventions include testosterone, testosterone undecanoate, and dutasteride.

At a glance

• Umbrella term: 6 Mondo subtypes
• Cohort genes: 3
• GWAS associations: 136
• ClinVar variants: 2
• Clinical trials: 197

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hypogonadism
Mondo ID	MONDO:0002146
MeSH	D007006
DOID	DOID:1924
NCIT	C9227
SNOMED CT	48130008
UMLS	C0020619
MedGen	5711
Is cancer (heuristic)	no

Also known as: gonadotropin deficiency · hypogonadotropism

Data availability: 2 ClinVar variants · 136 GWAS associations (5 studies) · 1 GenCC gene-disease record · 4 cell lines.

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › gonadal disorder › hypogonadism

Related subtypes (5): precocious puberty, disorder of sexual differentiation, testicular disorder, ovarian disorder, gonadoblastoma

Subtypes (6): gonadal dysgenesis, eunuchism, hypogonadism, male, hypogonadotropic hypogonadism, Slti-Salem syndrome, weinstein kliman scully syndrome

Genetics & variants

GWAS landscape

136 GWAS associations across 5 studies. Top hits map to 25 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs1799941	1e-136	SHBG	G	0.24
rs112800586	3e-119	LINC03114 - NOLC1P1	G	0.15
rs111386834	4e-96	LINC03114 - NOLC1P1	C	0.15
rs10822160	1e-70	JMJD1C	G	0.14
rs10761752	3e-55	JMJD1C	C	0.14
rs2883091	3e-45	RTL9	G	0.09
rs10521528	1e-38	RTL9	G	0.09
rs56196860	1e-36	FKBP4, ITFG2-AS1	C	0.31
rs1260326	4e-29	GCKR	T	0.09
rs28929474	1e-25	SERPINA1	C	0.33
rs727428	9e-23	SHBG - ATP1B2	C	0.18
rs738409	6e-20	PNPLA3	G	0.08
rs56332871	3e-19	NR2F2-AS1	C	0.07
rs34666276	3e-15	FLJ40194, ZNF652	C	0.07
rs28397663	4e-15	FLJ40194	C	0.07
rs8061590	2e-14	ATP2A1	G	0.06
rs5918764	6e-14	AR	A	0.06
rs8023580	9e-14	NR2F2-AS1	C	0.07
rs1553344333	1e-13	SRD5A2 - LINC01946	G	0.17
rs58528265	2e-13	ZNF652-AS1	AGCCTG	0.07
rs3976	7e-13	SERPINF2	G	0.06
rs9986829	9e-13	DGKB - GTF3AP5	G	0.06
rs11655056	1e-12	FLJ40194	C	0.06
rs79391862	3e-12	LINC02490 - WDR72	C	0.27
rs62033405	3e-12	FTO	C	0.06
rs12150660	4e-12	SHBG	T	0.26
rs4149056	2e-11	SLCO1B1	C	0.08
rs202200760	2e-11	NR2F6	G	0.13
rs73632187	3e-11	RNU6-394P - AR	G	0.07
rs6479897	4e-11	JMJD1C	T	0.11

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90503316	Pagadala MS	2025	0	0	Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.
GCST90503320	Pagadala MS	2025	0	0	Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.
GCST90503324	Pagadala MS	2025	0	0	Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.
GCST90503328	Pagadala MS	2025	0	0	Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.
GCST90570530	Pagadala MS	2025	0	0	Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	7
Tier 2: splice/UTR	2
Tier 3: regulatory	3
Tier 4: intronic/intergenic	38

MAF distribution

Bucket	Variants
common (>=0.05)	48
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	2

Functional consequences

Consequence	Count
intron_variant	26
intergenic_variant	12
missense_variant	7
regulatory_region_variant	3
5_prime_UTR_variant	1
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs1799941	17	7630105	G>A,T	0.05	5_prime_UTR_variant	SHBG	1e-136	Tier 2: splice/UTR
rs112800586	X	8948222	G>A,T	0.05	intergenic_variant	LINC03114 - NOLC1P1	3e-119	Tier 4: intronic/intergenic
rs111386834	X	8938654	T>C	0.05	intergenic_variant	LINC03114 - NOLC1P1	4e-96	Tier 4: intronic/intergenic
rs10822160	10	63353036	T>A,G	0.05	intron_variant	JMJD1C	1e-70	Tier 4: intronic/intergenic
rs10761752	10	63400561	T>C	0.05	intron_variant	JMJD1C	3e-55	Tier 4: intronic/intergenic
rs2883091	X	110440911	G>C	0.05	intron_variant	RTL9	3e-45	Tier 4: intronic/intergenic
rs10521528	X	110445924	A>G	0.05	intron_variant	RTL9	1e-38	Tier 4: intronic/intergenic
rs56196860	12	2799164	C>A	0.05	missense_variant	FKBP4, ITFG2-AS1	1e-36	Tier 1: coding
rs1260326	2	27508073	T>A,C,G	0.05	missense_variant	GCKR	4e-29	Tier 1: coding
rs28929474	14	94378610	C>A,G,T	0.05	missense_variant	SERPINA1	1e-25	Tier 1: coding
rs727428	17	7634474	T>A,C,G	0.05	regulatory_region_variant	SHBG - ATP1B2	9e-23	Tier 3: regulatory
rs738409	22	43928847	C>A,G,T	0.05	missense_variant	PNPLA3	6e-20	Tier 1: coding
rs56332871	15	96171587	C>A,T	0.05	intron_variant	NR2F2-AS1	3e-19	Tier 4: intronic/intergenic
rs34666276	17	49302124	T>A,C,G	0.05	intron_variant	FLJ40194, ZNF652	3e-15	Tier 4: intronic/intergenic
rs28397663	17	49250821	C>T	0.05	intron_variant	FLJ40194	4e-15	Tier 4: intronic/intergenic
rs8061590	16	28883809	A>C,G	0.05	intron_variant	ATP2A1	2e-14	Tier 4: intronic/intergenic
rs5918764	X	67717865	A>G,T	0.05	intron_variant	AR	6e-14	Tier 4: intronic/intergenic
rs8023580	15	96165062	T>C	0.05	intron_variant	NR2F2-AS1	9e-14	Tier 4: intronic/intergenic
rs1553344333	2	31764291	GGAGTATGTTCTTGCTGAT>GA	0.05	regulatory_region_variant	SRD5A2 - LINC01946	1e-13	Tier 3: regulatory
rs58528265	17	49367211	A>AG,AGCCCG,AGCCTG,AGCTG	0.05	intron_variant	ZNF652-AS1	2e-13	Tier 4: intronic/intergenic
rs3976	17	1749797	G>A,T	0.05	intron_variant	SERPINF2	7e-13	Tier 4: intronic/intergenic
rs9986829	7	14979634	G>A,C	0.05	intergenic_variant	DGKB - GTF3AP5	9e-13	Tier 4: intronic/intergenic
rs11655056	17	49286745	C>G,T	0.05	intron_variant	FLJ40194	1e-12	Tier 4: intronic/intergenic
rs79391862	15	53447229	A>C		intron_variant	LINC02490 - WDR72	3e-12	Tier 4: intronic/intergenic
rs62033405	16	53788475	C>T	0.05	intron_variant	FTO	3e-12	Tier 4: intronic/intergenic
rs12150660	17	7618597	G>T	0.05	intron_variant	SHBG	4e-12	Tier 4: intronic/intergenic
rs4149056	12	21178615	T>A,C	0.05	missense_variant	SLCO1B1	2e-11	Tier 1: coding
rs202200760	19	17236045	G>C	0.05	missense_variant	NR2F6	2e-11	Tier 1: coding
rs73632187	X	67105003	G>A	0.05	intergenic_variant	RNU6-394P - AR	3e-11	Tier 4: intronic/intergenic
rs6479897	10	63376868	C>T	0.05	intron_variant	JMJD1C	4e-11	Tier 4: intronic/intergenic

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 pathogenic, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
1183968	NM_152515.5(CKAP2L):c.1463_1467del (p.Thr488fs)	CKAP2L	Pathogenic	criteria provided, single submitter
1676256	NM_017563.5(IL17RD):c.1371T>G (p.Ile457Met)	IL17RD	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
SOHLH1	Limited	Autosomal recessive	hypogonadism	5

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SOHLH1	Orphanet:399805	Male infertility with azoospermia or oligozoospermia due to single gene mutation
IL17RD	Orphanet:478	Kallmann syndrome
CKAP2L	Orphanet:3255	Filippi syndrome

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SOHLH1	HGNC:27845	ENSG00000165643	Q5JUK2	Spermatogenesis- and oogenesis-specific basic helix-loop-helix-containing protein 1	gencc
IL17RD	HGNC:17616	ENSG00000144730	Q8NFM7	Interleukin-17 receptor D	clinvar
CKAP2L	HGNC:26877	ENSG00000169607	Q8IYA6	Cytoskeleton-associated protein 2-like	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SOHLH1	Spermatogenesis- and oogenesis-specific basic helix-loop-helix-containing protein 1	Transcription regulator of both male and female germline differentiation.
IL17RD	Interleukin-17 receptor D	Feedback inhibitor of fibroblast growth factor mediated Ras-MAPK signaling and ERK activation.
CKAP2L	Cytoskeleton-associated protein 2-like	Microtubule-associated protein required for mitotic spindle formation and cell-cycle progression in neural progenitor cells.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	2.8×	0.587
Other/Unknown	2	1.2×	0.587

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SOHLH1	Transcription factor	no		bHLH_dom, HLH_DNA-bd_sf, TCFL5/SOLH1/2
IL17RD	Other/Unknown	no		SEFIR_dom, IL17R_D_N, Toll_tir_struct_dom_sf
CKAP2L	Other/Unknown	no		CKAP2_C, CKAP2-like

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
anterior cingulate cortex	1
primordial germ cell in gonad	1
right frontal lobe	1
mammary duct	1
oocyte	1
secondary oocyte	1
embryo	1
ganglionic eminence	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SOHLH1	70	tissue_specific	yes	right frontal lobe, primordial germ cell in gonad, anterior cingulate cortex
IL17RD	236	broad	yes	secondary oocyte, oocyte, mammary duct
CKAP2L	149	ubiquitous	marker	ventricular zone, ganglionic eminence, embryo

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SOHLH1	1,483
IL17RD	981
CKAP2L	733

Structural data

PDB: 0 · AlphaFold-only: 3 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
IL17RD	Q8NFM7	69.68
SOHLH1	Q5JUK2	58.62
CKAP2L	Q8IYA6	54.68

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 3 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
MAP2K and MAPK activation	1	285.5×	0.004	IL17RD

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
oocyte differentiation	1	2106.5×	0.002	SOHLH1
negative regulation of epithelial to mesenchymal transition	1	205.5×	0.012	IL17RD
negative regulation of transforming growth factor beta receptor signaling pathway	1	86.9×	0.019	IL17RD
spermatogenesis	1	17.6×	0.068	SOHLH1
cell differentiation	1	14.6×	0.068	SOHLH1

Therapeutics

Drugs indicated for this disease

15 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Choriogonadotropin Alfa	Approved (phase 4)
Estradiol	Approved (phase 4)
Estradiol Valerate	Approved (phase 4)
Estrogens, Conjugated	Approved (phase 4)
Estrogens, Esterified	Approved (phase 4)
Fluoxymesterone	Approved (phase 4)
Follitropin	Approved (phase 4)
Follitropin Alfa	Approved (phase 4)
Follitropin Beta	Approved (phase 4)
Methyltestosterone	Approved (phase 4)
Norethindrone Acetate	Approved (phase 4)
Testosterone	Approved (phase 4)
Testosterone Cypionate	Approved (phase 4)
Testosterone Enanthate	Approved (phase 4)
Testosterone Undecanoate	Approved (phase 4)
Cholecalciferol	Phase 3 (in late-stage trials)
Corifollitropin Alfa	Phase 3 (in late-stage trials)
Dutasteride	Phase 3 (in late-stage trials)
Gonadotropin, Chorionic	Phase 3 (in late-stage trials)
Insulin Human	Phase 3 (in late-stage trials)
Letrozole	Phase 3 (in late-stage trials)
Menotropins	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Anastrozole, Clomiphene, Enclomiphene, KISSPEPTIN-10, Ketoconazole, Leuprolide, Lutropin Alfa, Naloxone.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 3

Druggability breadth: 0 of 3 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SOHLH1	0	0
IL17RD	0	0
CKAP2L	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	3	SOHLH1, IL17RD, CKAP2L

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SOHLH1	0	—
IL17RD	0	—
CKAP2L	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 197.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	52
PHASE2	44
PHASE4	42
PHASE3	31
PHASE1	20
PHASE2/PHASE3	3
PHASE1/PHASE2	3
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06385509	PHASE4	ACTIVE_NOT_RECRUITING	A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
NCT06455969	PHASE4	RECRUITING	Adaptions and Resiliency to Multi-Stressor OpeRations
NCT00194675	PHASE4	COMPLETED	TRADE-Testosterone Replacement and Dutasteride Effectiveness
NCT00240981	PHASE4	TERMINATED	TOM: Testosterone in Older Men With Sarcopenia
NCT00287586	PHASE4	COMPLETED	Testosterone Replacement in Older Men and Atherosclerosis Progression
NCT00304213	PHASE4	WITHDRAWN	Does Testosterone Improve Function in Hypogonadal Older Men
NCT00349362	PHASE4	COMPLETED	Testosterone for Men With Insulin Treated Type 2 Diabetes
NCT00421460	PHASE4	COMPLETED	The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction
NCT00440440	PHASE4	WITHDRAWN	Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes
NCT00487734	PHASE4	COMPLETED	Effect of Testosterone Replacement on Insulin Resistance
NCT00504712	PHASE4	COMPLETED	Testosterone for Peripheral Vascular Disease
NCT00700024	PHASE4	UNKNOWN	Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men
NCT00710827	PHASE4	WITHDRAWN	Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
NCT00752869	PHASE4	COMPLETED	Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01084369	PHASE4	TERMINATED	Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism
NCT01092858	PHASE4	TERMINATED	NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
NCT01107067	PHASE4	COMPLETED	Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism
NCT01123278	PHASE4	COMPLETED	Testosterone Replacement in Metabolic Syndrome and Inflammation
NCT01127659	PHASE4	COMPLETED	Testosterone Replacement in Men With Diabetes and Obesity
NCT01160341	PHASE4	COMPLETED	Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism
NCT01560546	PHASE4	COMPLETED	Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)
NCT01689896	PHASE4	WITHDRAWN	Testosterone and Pain Sensitivity
NCT01748370	PHASE4	COMPLETED	Vitamin D Treatment and Hypogonadism in Men
NCT01893281	PHASE4	COMPLETED	The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
NCT02102646	PHASE4	COMPLETED	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
NCT02111434	PHASE4	COMPLETED	Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
NCT02111473	PHASE4	COMPLETED	The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism
NCT02366975	PHASE4	COMPLETED	TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST
NCT02433730	PHASE4	COMPLETED	Testosterone Therapy in Hypogonadal Men Treated With Opioids
NCT02937740	PHASE4	COMPLETED	Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
NCT02959853	PHASE4	COMPLETED	Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
NCT03057899	PHASE4	COMPLETED	Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS
NCT03126656	PHASE4	COMPLETED	Effects of Testosterone on Myocardial Repolarization
NCT03518034	PHASE4	COMPLETED	A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
NCT03619330	PHASE4	COMPLETED	Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.
NCT03887936	PHASE4	COMPLETED	Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
NCT04274894	PHASE4	COMPLETED	A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
NCT04320745	PHASE4	COMPLETED	A Study to Evaluate Androderm®’s Effect on Blood Pressure in Adult Hypogonodal Male Participants
NCT04456296	PHASE4	COMPLETED	A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TESTOSTERONE	4	50
TESTOSTERONE UNDECANOATE	4	14
DUTASTERIDE	4	7
ALENDRONIC ACID	4	6
CLOMIPHENE	4	3
GONADORELIN ACETATE	4	3
TESTOSTERONE ENANTHATE	4	3
FINASTERIDE	4	2
GOSERELIN	4	2
KETOCONAZOLE	4	2
LEVOKETOCONAZOLE	4	2
SODIUM CHLORIDE	4	2
TESTOSTERONE CYPIONATE	4	2
ANAKINRA	4	1
ANASTROZOLE	4	1
CORIFOLLITROPIN ALFA	4	1
ESTRADIOL	4	1
GONADOTROPIN, CHORIONIC	4	1
LETROZOLE	4	1
LIRAGLUTIDE	4	1
PIOGLITAZONE	4	1
TRIPTORELIN	4	1
ENCLOMIPHENE	3	3
ACYLINE	2	4
FISPEMIFENE	2	1
KISSPEPTIN	2	1
STANOLONE	2	1
CHEMBL4746472	0	29
CHEMBL4073387	0	3
CHEMBL1233255	0	2